Breaking News, Financial News

Financial Report: WuXi PharmaTech 3Q10

Growth in the quarter was attributed to growth in Lab Services and Manufacturing Services.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi PharmaTech 3Q10 3Q Revenues: $83.8 million (+20%) 3Q Earnings: $44.3 million (+209%) YTD Revenues: $245.5 million (+25%) YTD Earnings: $73.5 million (+80%) Comments: Growth in the quarter was attributed to growth in Lab Services and Manufacturing Services. China-based Lab Services revenues were up 19% in the quarter to $57.1 million. U.S Lab Services revenues increased 20% to $19.6 million. Manufacturing revenues were $7.1 million (+23%)....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters